Skip to content
DataLookout
Menu

MINUTENCT06031233

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

StatusRecruiting
PhasePhase 4
SponsorIsala
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 8 words
    • Enrollment increased: 776 → 1082 participants
    • Interventions modified
    • Trial arms changed: 8 → 11
  2. Notable Primary completion date: Jul 2026 to Jul 2028v4 Show 4 more changesShow less
    • Enrollment target: 679 to 776
    • Study completion date: Dec 2026 to Dec 2028
    • Interventions: Atezolizumab (Drug), Bevacizumab (Drug), Durvalumab (Drug), Ipilimumab (Drug), Nivolumab (Drug), Pembrolizumab (Drug), Trastuzumab (Drug) to Atezolizumab (Drug), Bevacizumab (Drug), Durvalumab (Drug), Ipilimumab (Drug), Nivolumab (Drug), Pembrolizumab (Drug), Rituximab (Drug)…
    • Study arms: 7 to 8
  3. Notable Primary completion date: Jul 2024 to Jul 2026
    • Study completion date: Dec 2024 to Dec 2026
    v3
  4. Notable Trial status: Not Yet Recruiting to Recruitingv2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of infusion related reactions
Timeframe: During or within 30 minutes after the end of the infusion

Secondary (1)

Plasma levels of the administered mAb

Arms and interventions

NivolumabExperimental

If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.

PembrolizumabExperimental

If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.

ipilimumabExperimental

If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.

DurvalumabExperimental

If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.

AtezolizumabExperimental

If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.

bevacizumabExperimental

If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.

TrastuzumabExperimental

If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.

RituximabExperimental

If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 15 minutes in the following cycles.

InfliximabExperimental

If no infusion reaction has occurred after 6 cycles, infusion time will stepwise be shortened to 10 minutes in the following cycles.

VedolizumabExperimental

If no infusion reaction has occurred after 2 cycles, infusion time will stepwise be shortened to 1 minutes in the following cycles.

TocilizumabExperimental

If no infusion reaction has occurred after 2 cycles, infusion time will stepwise be shortened to 10 minutes in the following cycles.

Drugs: Nivolumab, Pembrolizumab, Ipilimumab, Durvalumab, Atezolizumab, Bevacizumab, Trastuzumab, Rituximab, Infliximab, Vedolizumab, Tociliuzumab

Sites

1 site in 1 country

  • Isala HospitalZwolle, Netherlands